The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response
V. Norris, J. Bentley, S. Kent, M. Boyce, Z. Diamant, D. Singh, B. O‘Connor (Stevenage, London, Manchester, United Kingdom; Leiden, Netherlands)
Source: Annual Congress 2011 - New treatments for airway disease
Session: New treatments for airway disease
Session type: Oral Presentation
Number: 3424
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Norris, J. Bentley, S. Kent, M. Boyce, Z. Diamant, D. Singh, B. O‘Connor (Stevenage, London, Manchester, United Kingdom; Leiden, Netherlands). The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response. Eur Respir J 2011; 38: Suppl. 55, 3424
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Source: Eur Respir J 2013; 41: 46-52 Year: 2013
The inhaled PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Effect of a novel inhaled glucocorticoid, ciclesonide, on an allergen-induced asthmatic response in rats and its prolonged anti-inflammatory activity in vitro Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
The major house dust mite allergen Der p2 induces IL-8, GM-CSF and ICAM-1 expression in human bronchial epithelial cells partly by a MAPK kinase dependent pathway Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005
17-beclomethasone monopropionate or inhibition of MAPK p38 signalling abolish IL-8 release stimulated by cigarette smoke extract or acrolein in normal human airway smooth muscle cells Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Cilomilast, a second generation phosphodiestease 4 inhibitor, in combination with PGE2 attenuates fMLP, IL-8 and cigarette smoke-induced effects on the mechanical and functional properties of neutrophils Source: Eur Respir J 2001; 18: Suppl. 33, 161s Year: 2001
Effect of PDE4 inhibitors on MAPK activation and IL-8 production on A549 cells following the induction of oxidative stress Source: Eur Respir J 2005; 26: Suppl. 49, 99s Year: 2005
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
Effect of combined leukotriene, histamine antagonism on the early response to inhaled allergen Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008